NextCure

NXTCNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$23.711 M

$5.18 -5.13%

Close of 22 Sept 2026

Revenue

—

Not reported

Earnings

-$55.8M

Loss-making

Shares outstanding

4,577,359

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 499 →

#386Aytu BiopharmaAYTU$23.9M
#387Radiopharm TheranosticsRADX$23.9M
#388NextCureNXTC$23.7M
#389Universe PharmaceuticalsUPC$23.4M
#390Korsana BiosciencesKRSA$23.4M

Insiders buying

All insider buying →

2 open-market purchases by officers and directors of NextCure, worth $1.71M. Grants and option exercises are excluded.

ADAR1 Capital Management, LLC, Daniel Schneeberger$1.62M
329,153 shares at $4.93 on 30 Jul 2026 · filed 3 Aug 2026
ADAR1 Capital Management, LLC, Daniel Schneeberger$87.7K
17,608 shares at $4.98 on 27 Jul 2026 · filed 29 Jul 2026

What if NextCure were worth as much as…

Open the what-if tool →

Gold $30.2T

$6,605,112

Per share 1,275,118× higher

Bitcoin $1.74T

$380,493.43

Per share 73,454× higher

Nvidia $5.52T

$1,205,011

Per share 232,628× higher

Or at a round number

$50.0M $100.0M $200.0M $500.0M

Where these numbers come from

Share counts and financials for NextCure are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.